An observational study in Obesity, Sarcopenia and Sarcopenic Obesity, sponsored by Sengkang General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-15.
Sponsored by Sengkang General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Obesity with a site in Singapore — 17 open to participants now, 25 under way, 1 of them phase 3. Obesity · Singapore.
Among the 83 studies in Obesity with a site in Singapore, this one is the 4th largest by planned enrollment of the 15 observational ones that give a count, is one of 6 that started in 2023, is one of 15 observational ones, reaches primary completion later than 11 of the 24 other live ones, and was the 58th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →17 of the 83 studies in Obesity with a site in Singapore are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65 · Healthy volunteers
National University of Singapore · Sites in Singapore
Ages 21–70 · Healthy volunteers
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 21 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 70 across the 68 interventional studies, 200 across the 15 observational. Of the 45 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 83 have an industry lead sponsor. The 10 most frequent:
Sengkang General Hospital is the lead sponsor of 16 studies on the registry; 10 are open to participants now.
Sengkang General Hospital has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
9 of the studies in Obesity with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07738614Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight | 2026-12 |
| NCT07225556Eli Lilly and CompanyA Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy | 2026-12 |
| NCT07444073National University of SingaporeAssessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | 2026-12-31 |
| NCT06363253Sengkang General HospitalPilot Study of the Human Metagenome in Metabolic Diseases | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Obesity with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.
Recruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing.
We hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.
The human metagenome comprises all nucleotide sequences isolated from all organisms living on and within an individual and has been shown to have significant alterations in relation to certain diseased states related to chronic inflammation, such as obesity and sarcopenia.
The gut bacteriome, and more recently the virome, has been shown to be significantly correlated with the obese phenotype, while gut microbiome dysbiosis is known to occur in individuals with sarcopenia. Clinically, there is an unmet clinical need to better personalize the treatment of patients with metabolic disorders such as obesity and metabolic syndrome, and patients suffering from sarcopenia and frailty as a result of aging. However, the literature regarding the metagenomic signatures associated with these disorders, in particular the non-bacteriome species, bacterial metabolites, and their relationship with host metabolism, were scarce.
Thus we hypothesize, that the human metagenome and metabolome, may play a role in influencing chronic inflammatory disorders related to metabolic disorders, such as obesity and diseases related to aging like sarcopenia and aging.
This is a cohort study, involving metagenomic sequencing and metabolomic analysis, of patients metagenome and metabolome, in various diseased states. A cohort of healthy control patients without obesity or sarcopenia will also be recruited.
Samples collected will include fecal, salivary, serum, urine, mucosal samples for metagenomic sequencing and metabolomic testing.
Obese and sarcopenic patients will be recruited from patients from Sengkang General Hospital, opportunistically found during their management to be sarcopenic. Obese patients will be recruited from patients who are seen in the Sengkang General Hospital Weight Management Clinic.
Controls are recruited from patients who are on follow-up for other non-related conditions found opportunistically to fit the inclusion criteria, as well as healthy volunteers.
Inclusion Criteria (obese cohort):
Inclusion Criteria (sarcopenic cohort):
Inclusion Criteria (control cohort):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with BMI \> 27.5 kg/m2
Other: No specific intervention
Patients who are sarcopenic, defined by the Asian Working Group on Sarcopenia 2014 criteria, which is defined as 1. having low handgrip strength (\<26kg for males; \<18kg for females) AND/OR 2. Low gait speed (\<0.8m/s) AND 3. Low muscle mass (\<7.0kg/m2 for males; \<5.7kg/m2 for females)
Other: No specific intervention
Healthy volunteers who are not obese (BMI \<27.5kg/m2), OR who are screened and found to not be sarcopenic
Other: No specific intervention
Patient will undergo their routine clinical treatment for their related clinical condition (eg. anti-obesity or bariatric intervention for obese group; muscle strengthening interventions or necessary treatment for their concomitant medical condition for the sarcopenia group). Follow-up testing will include repeat assessment of the subjects metagenome and metabolome over time, and after intervention Control subjects will have no interventions performed as well.
Metagenomic alterations
Metagenomic alterations in the DNA/ RNA sequences of the saliva, stool (+/- mucosal) metagenome over time
Time frame: Period of 1 year
Metabolomic alterations
Changes in serum and urinary charged metabolites and small molecules over time
Time frame: Period of 1 year
Plan to share: Undecided — Undecided at the moment. Deidentified data can potentially be shared following institutional review board and hospital permission.
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 40 months is close to that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sengkang General Hospital